Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT07017270

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07017270
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07017270. Randomized; no masking; primary purpose treatment. Start 2025-11-27 (actual); primary completion 2027-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
Acronym
GUARD-1
Condition
Kidney Disease, Chronic
Condition
Diabetes
Condition
Dialysis
Condition
End Stage Kidney Disease (ESRD)
Intervention (Drug)
Semaglutide Pen
Lead sponsor
Unity Health Toronto (class: other)

Record details

Record id
cardio:ct-nct07017270
Content hash
97fd1e3585d5b6a9f5cb803a774816c6ceb54c8c1e152dba93e3c4ebf36aa93e